NCT06329791 - A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

November 30, 2025

Conditions

Dry Eye Disease

Interventions

DRUG

AZR-MD-001

AZR-MD-001 sterile ophthalmic ointment 0.5%

OTHER

Vehicle

AZR-MD-001 Vehicle

Trial Locations (16)

16066

Scott & Christie and Associates, PC, Cranberry Township

24502

Piedmont Eye Center, Lynchburg

27502

NC Eye Associates, Apex

27529

Oculus Research, Inc., Garner

28150

CORE, Shelby

37072

Advancing Vision Research (AVR) - Goodlettsville, Goodlettsville

37167

Advancing Vision Research (AVR) - Smyrna, Smyrna

38119

Total Eye Care, Memphis

40206

The Eye Care Institute/Butchertown Clinical Trials, Louisville

47203

Pankratz Eye Institute, Columbus

60062

Wyse Eyecare, Northbrook

63131

Ophthalmology Associates, St Louis

85225

Arizona Eye Center, Chandler

90505

NVISION Clinical Research, Torrance

91204

Global Research Management, Inc, Glendale

92663

Eye Research Foundation, Newport Beach